Terms: = Cervical cancer AND MYO5A, Q9Y4I1, MYR12, MYO5, MYH12, GS1, ENSG00000197535, 4644
3 results:
1. Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis.
Barrington DA; Riedinger C; Haight PJ; Tubbs C; Cohn DE
Gynecol Oncol; 2022 Jun; 165(3):500-505. PubMed ID: 35422338
[TBL] [Abstract] [Full Text] [Related]
2. Integrative data mining and meta-analysis to investigate the prognostic role of microRNA-200 family in various human malignant neoplasms: A consideration on heterogeneity.
Yuan L; Bing Z; Yan P; Li R; Wang C; Sun X; Yang J; Shi X; Zhang Y; Yang K
Gene; 2019 Oct; 716():144025. PubMed ID: 31394177
[TBL] [Abstract] [Full Text] [Related]
3. Can a metastatic gene expression profile outperform tumor size as a predictor of occult lymph node metastasis in oral cancer patients?
Méndez E; Lohavanichbutr P; Fan W; Houck JR; Rue TC; Doody DR; Futran ND; Upton MP; Yueh B; Zhao LP; Schwartz SM; Chen C
Clin Cancer Res; 2011 Apr; 17(8):2466-73. PubMed ID: 21300763
[TBL] [Abstract] [Full Text] [Related]
